Erasca, Inc.
$21.71
▲
7.29%
2026-04-21 06:41:01
www.erasca.com
NMS: ERAS
Explore Erasca, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.91 B
Current Price
$21.71
52W High / Low
$19.78 / $1.06
Stock P/E
—
Book Value
$1.14
Dividend Yield
—
ROCE
-35.74%
ROE
-33.27%
Face Value
—
EPS
$-0.44
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
103
Beta
1.05
Debt / Equity
14.5
Current Ratio
10.04
Quick Ratio
10.04
Forward P/E
-31.41
Price / Sales
—
Enterprise Value
$5.06 B
EV / EBITDA
-39.42
EV / Revenue
—
Rating
Buy
Target Price
$18.1
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Precigen, Inc. | $4.11 | — | $1.45 B | — | -90.19% | -5.72% | $5.46 / $1.23 | $0.06 |
| 2. | Sol-Gel Technologies Ltd. | $70 | — | $228.83 M | — | -31.74% | -23.72% | $97.97 / $4.11 | $8.19 |
| 3. | IDEAYA Biosciences, Inc. | $33.6 | — | $2.95 B | — | -15.17% | -10.92% | $39.28 / $16.07 | $11.65 |
| 4. | PharmaCyte Biotech, Inc. | $0.76 | — | $7.82 M | — | -8.38% | -8.24% | $1.51 / $0.63 | $3.59 |
| 5. | Vera Therapeutics, Inc. | $41.61 | — | $3.02 B | — | -46.31% | -50.71% | $56.05 / $18.76 | $8.48 |
| 6. | Pliant Therapeutics, Inc. | $1.29 | — | $79.87 M | — | -74.87% | -61.55% | $1.95 / $1.09 | $2.95 |
| 7. | RenovoRx, Inc. | $1 | — | $45.05 M | — | -176.68% | -2.26% | $1.45 / $0.7 | $0.15 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -32.6 M | -32.55 M | -30.62 M | -35.63 M | -35.71 M | — |
| Net Profit | -29.09 M | -30.61 M | -33.88 M | -30.97 M | -32.23 M | — |
| EPS in Rs | -0.09 | -0.1 | -0.11 | -0.1 | -0.1 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -131.41 M | -157.09 M | -141.53 M | -145.45 M |
| Net Profit | -124.55 M | -161.65 M | -125.04 M | -242.81 M |
| EPS in Rs | -0.4 | -0.52 | -0.4 | -0.78 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 396.15 M | 502.53 M | 395.3 M | 514.91 M |
| Total Liabilities | 70.98 M | 79.03 M | 78.61 M | 103.06 M |
| Equity | 325.17 M | 423.5 M | 316.69 M | 411.85 M |
| Current Assets | 286.24 M | 308.79 M | 320.68 M | 444.5 M |
| Current Liabilities | 28.51 M | 31.39 M | 26.16 M | 48.69 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -95.45 M | -109.42 M | -101.22 M | -103.26 M |
| Investing CF | 100.42 M | -156.62 M | -91.22 M | -71.08 M |
| Financing CF | 1.1 M | 240.7 M | 1.29 M | 98.08 M |
| Free CF | -105.08 M | -131.98 M | -122.99 M | -119.81 M |
| Capex | -9.63 M | -22.56 M | -21.77 M | -16.55 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -29.28% | 48.5% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.